Successful treatment of hepatocellular carcinoma with regorafenib after sorafenib-induced hypersensitivity

Naoki Yoshioka, Teiji Kuzuya, Takanori Ito, Yoji Ishizu, Takashi Honda, Tetsuya Ishikawa, Masatoshi Ishigami, Mitsuhiro Fujishiro

Research output: Contribution to journalArticle

Abstract

Sorafenib and regorafenib are tyrosine kinase inhibitors that are used in the treatment of hepatocellular carcinoma and which have similar chemical structures and toxicity profiles. We herein report a case in which regorafenib treatment could be continued for 10 months and stable disease could be maintained for a long period despite the discontinuation of sorafenib due to grade 4 liver injury and grade 3 fever. The severe adverse events could be attributed to drug hypersensitivity, since a drug-induced lymphocyte stimulation test (DLST) indicated sensitivity to sorafenib. A DLST for regorafenib was negative. This is the first report showing that regorafenib could be safely administered after the discontinuation of sorafenib due to hypersensitivity.

Original languageEnglish
Pages (from-to)2803-2808
Number of pages6
JournalInternal Medicine
Volume58
Issue number19
DOIs
Publication statusPublished - 2019
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Internal Medicine

Fingerprint Dive into the research topics of 'Successful treatment of hepatocellular carcinoma with regorafenib after sorafenib-induced hypersensitivity'. Together they form a unique fingerprint.

  • Cite this

    Yoshioka, N., Kuzuya, T., Ito, T., Ishizu, Y., Honda, T., Ishikawa, T., Ishigami, M., & Fujishiro, M. (2019). Successful treatment of hepatocellular carcinoma with regorafenib after sorafenib-induced hypersensitivity. Internal Medicine, 58(19), 2803-2808. https://doi.org/10.2169/internalmedicine.2812-19